Literature DB >> 18478934

[Multi-center randomized clinical study on Shenqi-fuzheng injection combined with chemotherapy in the treatment for lung cancer].

Hong-Sheng Lin1, Dao-Rui Li.   

Abstract

OBJECTIVE: To investigate the effect of Shenqi-fuzheng injection combined with chemotherapy on the quality of life in lung cancer patient.
METHODS: 232 pathologically confirmed nonsmall cell lung cancer patients were enrolled into this multi-center randomized trial. Of these 232 patients, 116 cases were treated with chemotherapy alone (chemotherapy group), another 116 with chemotherapy combined with Shenqi-fuzheng injection produced by Lizhu Company (Shenqi-fuzheng group). Life quality of these patients were evaluated using the QOL scale of European Organization for Research on Treatment of Cancer (QLQ-C30) and the functional living index-cancer.
RESULTS: Compared with chemotherapy group, Life quality and symptoms were improved in the Shenqi-fuzheng group, which including lassitude, deficient in breath, pain, fullness in chest and hypochondrium, excessive phlegm, cough, complexion whiteness. Response rate to chemotherapy was also improved. No AE and SAE were observed in the Shenqi-fuzheng group.
CONCLUSION: Shenqi-fuzheng injection combined with chemotherapy is safe and effective in the treatment for non-small cell lung cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18478934

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  5 in total

1.  US National Cancer Institute-China Collaborative Studies on Chinese Medicine and Cancer.

Authors:  Libin Jia; Hongsheng Lin; Joost Oppenheim; O M Zack Howard; Jie Li; Huiting Fan; Zhizheng Zhao; William Farrar; Ying Zhang; Nancy Colburn; Matthew R Young; Weidong Li; David Newman; Barry R O'Keefe; John Beutler; Jikai Liu; Xiaojiang Hao; Xiaosheng Yang; Tengfei Ji; Jeffrey D White
Journal:  J Natl Cancer Inst Monogr       Date:  2017-11-01

2.  Long-Term Effectiveness of Combined Treatment with Traditional Chinese Medicine and Western Medicine on the Prognosis of Patients with Lung Cancer.

Authors:  Woung-Ru Tang; Sien-Hung Yang; Chih-Teng Yu; Chin-Chou Wang; Sheng-Teng Huang; Tzu-Hsin Huang; Ming-Chu Chiang; Yue-Cune Chang
Journal:  J Altern Complement Med       Date:  2016-03       Impact factor: 2.579

3.  Therapeutic applications of herbal medicines for cancer patients.

Authors:  Shu-Yi Yin; Wen-Chi Wei; Feng-Yin Jian; Ning-Sun Yang
Journal:  Evid Based Complement Alternat Med       Date:  2013-07-11       Impact factor: 2.629

Review 4.  Immunoregulation of Shenqi Fuzheng Injection Combined with Chemotherapy in Cancer Patients: A Systematic Review and Meta-Analysis.

Authors:  Yang Yang; Wang Ting; Liu Xiao; Fu Shufei; Tan Wangxiao; Wang Xiaoying; Gao Xiumei; Zhang Boli
Journal:  Evid Based Complement Alternat Med       Date:  2017-01-05       Impact factor: 2.629

5.  A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients.

Authors:  Qing Liu; Yanni Lou; Liya Li; Guowang Yang; Huijuan Cui; Zhiqiang Cheng; Yuan Li; Meng Liu; Chao Deng; Donggui Wan; Yongxia Yan; Liqun Jia
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.